VEXAS Syndrome: A Comprehensive Review of Clinical Mimickers and Differential Diagnosis at the Rheumatology–Haematology Interface
DOI:
https://doi.org/10.12775/JEHS.2026.88.69345Keywords
VEXAS syndrome, UBA1 mutation, Autoinflammatory diseases, Myelodysplastic syndromes, Diagnostic challenges, Relapsing polychondritis, Vasculitis, Neutrophilic dermatosesAbstract
VEXAS syndrome is a newly described autoimmune disorder in adults caused by a somatic mutation in the UBA1 gene located on the X chromosome, occurring almost exclusively in older men. The disease combines features of severe chronic inflammation with hematopoietic disorders, resulting in a heterogeneous and multi-organ clinical picture and frequent diagnostic difficulties. The aim of this study is to present the characteristics of VEXAS syndrome and discuss the most important diseases mimicking its course, with particular emphasis on differential diagnosis. The clinical picture of the syndrome includes recurrent fever, neutrophilic skin lesions, chondritis, vasculitis, lung involvement, and an increased tendency to thrombosis. Haematological abnormalities, primarily macrocytic anaemia and thrombocytopenia, often coexisting with myelodysplastic syndromes, are an integral part of the disease. A characteristic, though not pathognomonic, finding is the presence of cytoplasmic vacuoles in myeloid and erythroid precursors in the bone marrow. VEXAS syndrome can mimic many rheumatological, autoinflammatory, and haematological diseases, such as recurrent chondritis, Sweet's syndrome, or systemic vasculitis, and its course is often characterized by resistance to standard immunosuppressive treatment. Including VEXAS syndrome in the differential diagnosis of older men with unexplained inflammation and macrocytosis is crucial for shortening the time to diagnosis and implementing appropriate treatment.
References
Al-Hakim A, Savic S. An update on VEXAS syndrome. Expert Rev Clin Immunol. 2023;19(2):203–215. doi: 10.1080/1744666X.2023.2157262
Beck DB, Bodian DL, Shah V, et al. Genomic ascertainment for UBA1 variants and VEXAS syndrome: a population-based study. bioRxiv. 2022. doi: 10.1101/2022.07.27.22277962
Beck DB, Ferrada MA, Sikora KA, et al. Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med. 2020;383(27):2628–2638. doi: 10.1056/NEJMoa2026834
Bourbon E, Heiblig M, Valentin MG, et al. Therapeutic options in VEXAS syndrome: insights from a retrospective series. Blood. 2021;137(26):3682–3684. doi: 10.1182/blood.2020010177
Comont T, Heiblig M, Rivière E, et al. Azacitidine for patients with Vacuoles, E1 Enzyme, X-linked, Autoinflammatory, Somatic syndrome (VEXAS) and myelodysplastic syndrome: data from the French VEXAS registry. Br J Haematol. 2022;196(4):969–974. doi: 10.1111/bjh.17947
Diarra A, Duployez N, Fournier E, et al. Successful allogeneic hematopoietic stem cell transplantation in patients with VEXAS syndrome: a 2-center experience. Blood Adv. 2022;6(3):998–1003. doi: 10.1182/bloodadvances.2021005707
Farina N, Tomelleri A, Campochiaro C, Dagna L. Giant cell arteritis: Update on clinical manifestations, diagnosis, and management. Eur J Intern Med. 2023;107:17–26. doi: 10.1016/j.ejim.2022.10.025
Ferrada MA, Savic S, Cardona DO, et al. Translation of cytoplasmic UBA1 contributes to VEXAS syndrome pathogenesis. Blood. 2022;140(13):1496–1506. doi: 10.1182/blood.2022016301
Georgin‐Lavialle S, Terrier B, Guedon AF, et al. Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients. Br J Dermatol. 2022;186(3):564–574. doi: 10.1111/bjd.20805
Ghoufi L, Ortonne N, Ingen-Housz-Oro S, et al. Histiocytoid Sweet syndrome is more frequently associated with myelodysplastic syndromes than the classical neutrophilic variant: a comparative series of 62 patients. Medicine (Baltimore). 2016;95(15):e3033. doi: 10.1097/MD.0000000000003033
González García A, Fernández-Martín J, Robles Marhuenda Á. Idiopathic multicentric Castleman disease and associated autoimmune and autoinflammatory conditions: practical guidance for diagnosis. Rheumatology (Oxford). 2023;62(4):1426–1435. doi: 10.1093/rheumatology/keac481
Grayson PC, Patel BA, Young NS. VEXAS syndrome. Blood. 2021;137(26):3591–3594. doi: 10.1182/blood.2021011455
Groarke EM, Dulau-Florea AE, Kanthi Y. Thrombotic manifestations of VEXAS syndrome. Semin Hematol. 2021;58(4):230–238. doi: 10.1053/j.seminhematol.2021.10.003
Gurnari C, Mannion P, Pandit I, et al. UBA1 screening in sweet syndrome with hematological neoplasms reveals a novel association between VEXAS and chronic myelomonocytic leukemia. HemaSphere. 2022;6(10):e775. doi: 10.1097/HS9.0000000000000775
Hasserjian RP. Myelodysplastic Syndrome Updated. Pathobiology. 2019;86(1):7–13. doi: 10.1159/000489702
Heiblig M, Ferrada MA, Koster MJ, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140(2):140. doi: 10.1182/blood.2022016645
Jain H, Roy D, Mavidi S, et al. Elderly Onset Spondyloarthropathy and VEXAS Syndrome: A Case Report. Mediterr J Rheumatol. 2024;35(3):490–493. doi: 10.31138/mjr.271223.eos
Khitri M-Y, Guedon AF, Georgin-Lavialle S, et al. Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients. RMD Open. 2022;8:e002255. doi: 10.1136/rmdopen-2022-002255
Kottas K, Faltaka A, Katsifis G. VEXAS syndrome: an updated literature review. Eur J Rheumatol. 2025;12(3):0096. doi: 10.5152/eurjrheum.2025.24096
Kouranloo K, Ashley A, Zhao SS, Dey M. Pulmonary manifestations in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome: a systematic review. Rheumatol Int. 2023;43(6):1023–1032. doi: 10.1007/s00296-023-05295-w
Lacombe V, Beucher A, Urbanski G, et al. Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome. Exp Hematol Oncol. 2022;11(1):6. doi: 10.1186/s40164-022-00262-w
Loeza-Uribe MP, Hinojosa-Azaola A, Sánchez-Hernández BE, et al. VEXAS syndrome: Clinical manifestations, diagnosis, and treatment. Reumatol Clin (Engl Ed). 2024;20(1):47–56. doi: 10.1016/j.reumae.2023.12.004
Lyons HS, Quick V, Sinclair AJ, Nagaraju S, Mollan SP. A new era for giant cell arteritis. Eye (Lond). 2020;34(6):1013–1026. doi: 10.1038/s41433-019-0608-7
Magnol M, Couvaras L, Degboé Y, et al. VEXAS syndrome in a patient with previous spondyloarthritis with a favourable response to intravenous immunoglobulin and anti-IL17 therapy. Rheumatology (Oxford). 2021;60(9):e314–e315. doi: 10.1093/rheumatology/keab211
Mascaro JM, Rodriguez-Pinto I, Poza G, et al. Spanish cohort of VEXAS syndrome: clinical manifestations, outcome of treatments and novel evidences about UBA1 mosaicism. Ann Rheum Dis. 2023;82(12):1594–1605. doi: 10.1136/ard-2023-224204
Mekinian AM, Georgin-Lavaille S, Ferrada MA, et al. American College of Rheumatology Guidance Statement for Diagnosis and Management of VEXAS Developed by the International VEXAS Working Group Expert Panel. Arthritis Rheumatol. 2025 Aug 11. [Epub ahead of print]. doi: 10.1002/art.43287
Midtvedt O, Stray-Pedersen A, Andersson H, et al. A man in his sixties with chondritis and bone marrow failure. Tidsskr Nor Laegeforen. 2022;142(4). doi: 10.4045/tidsskr.21.0370
Muratore F, Marvisi C, Castrignanò P, et al. VEXAS syndrome: a case series from a single-center cohort of Italian patients with vasculitis. Arthritis Rheumatol. 2022;74(4):665–670. doi: 10.1002/art.42031
Nakajima H, Kunimoto H. VEXAS syndrome. Int J Hematol. 2025;122:341–350. doi: 10.1007/s12185-024-03799-9
Sekeres MA, Taylor J. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA. 2022;328(9):872–880. doi: 10.1001/jama.2022.14578
Shratz KE, DeZern AE. Genetic Predisposition to Myelodysplastic Syndrome in Clinical Practice. Hematol Oncol Clin North Am. 2020;34(2):333–356. doi: 10.1016/j.hoc.2019.10.002
Sterling D, Duncan ME, Philippidou M, et al. VEXAS syndrome (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) for the dermatologist. J Am Acad Dermatol. 2023;89(6):1209–1214. doi: 10.1016/j.jaad.2022.01.042
Suszek D, Dubaj M, Dembowska A, Bigosiński K. VEXAS syndrome — long recognised, recently named. Rheumatology Forum. 2023;9(4):186–191. doi: 10.5603/rf.97130
Tan IJ, Ferrada MA, Ahmad S, et al. Skin Manifestations of VEXAS Syndrome and Associated Genotypes. JAMA Dermatol. 2024;160(8):822–829. doi: 10.1001/jamadermatol.2024.1657
van der Geest KSM, Sandovici M, Brouwer E, Mackie SL. Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis. JAMA Intern Med. 2020;180(10):1295–1304. doi: 10.1001/jamainternmed.2020.3050
van der Made CI, Potjewijd J, Hoogstins A, et al. Adult-onset autoinflammation caused by somatic mutations in UBA1: a Dutch case series of patients with VEXAS. J Allergy Clin Immunol. 2022;149(1):432–439. doi: 10.1016/j.jaci.2021.05.014
Watanabe R, Kiji M, Hashimoto M. Vasculitis associated with VEXAS syndrome: a literature review. Front Med (Lausanne). 2022;9:983939. doi: 10.3389/fmed.2022.983939
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Hanna Aleksandrowicz, Zuzanna Kalinowska, Julia Sokołowska , Karolina Karska, Katarzyna Grunwald, Marcel Dawidowicz

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0
Stats
Number of views and downloads: 8
Number of citations: 0